Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNA043 ± canakinumab in inflammatory knee osteoarthritis
CTR20213160Phase 2Terminated
- Sponsor
- Novartis
- Start
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LNA043 in knee osteoarthritis (OA) (4 arms), sponsored by Novartis. Primary endpoints: Change in cartilage volume at primary region of interest assessed by MRI and Change in KOOS pain subscale score. Started Dec 2021; status: terminated.
02
Drugs
LNA043
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on CTR20213160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213160.